MedicNova (MNOV) reports positive results from Phase 1b trials of its pulmonary disease...

|By:, SA News Editor

MedicNova (MNOV) reports positive results from Phase 1b trials of its pulmonary disease treatment MN-221. The company says the majority of the subjects completed the study and there were no clinically significant safety concerns. In addition, preliminary pharmacokinetic and efficacy findings were encouraging. Shares -2.4% AH.